The results demonstrated that HCC tissues from patients who received sitagliptin showed higher CD8+ T cell infiltration, while HCC tissues from patients who did not receive sitagliptin showed significantly lower CD8 T cell infiltration (Fig. 7f), indicating that sitagliptin could enhance lymphocyte trafficking. The gene discussed is CD8A; the disease is hepatocellular carcinoma.